Share on

Global Zika Virus Vaccines Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Type (Therapeutic Vaccines, Preventive Vaccines), End-user & Region – Industry Forecast (2023 to 2028)

Published: March, 2023
ID: 5810
Pages: 175
Formats: report pdf report excel report power bi report ppt

Zika Virus Vaccines Market Size (2023 to 2028)

The size of the global Zika virus vaccine market is estimated to be growing at a CAGR of 5.4% during the forecast period. As a result, the market is predicted to value USD 23.27 billion by 2028 from USD 17.89 billion in 2023.

MARKET DRIVERS:

The growing incidence of the Zika virus globally especially in regions with favorable mosquito vectors is one of the major factors propelling the market growth. Zika virus is a mosquito-borne viral infection. The impact of the Zika virus has reached various parts of the world due to its association with severe birth defects and neurological disorders. As per the data published by the World Health Organization (WHO), 91 countries and territories have experienced the transmission of the Zika virus since 2007. The increasing incidence of the Zika virus has fuelled awareness among people and healthcare professionals regarding the risks of the infection, especially for pregnant women and their unborn children. This has resulted in the increased demand for effective preventive measures such as the development and adoption of Zika virus vaccines. The urgency to combat the spread of the Zika virus has fuelled the demand for Zika virus vaccines and this trend is likely to continue in the coming years and drive the market growth.

The growing public health awareness and an increasing number of initiatives from governments further contribute to the Zika virus vaccines market growth. The awareness of the risks and consequences of Zika virus infections among people has increased considerably in recent years. On the other hand, governmental organizations and public health organizations have been taking several measures to control and limit the transmission of the Zika virus. The governmental organizations of some countries have been offering financial support and research grants to support the R&D of Zika virus vaccines. Such factors drive the development and adoption of Zika virus vaccines and support market growth.

The supportive reimbursements from governments, technological advancements, rising focus on immunization, increasing healthcare expenditure, growing disposable income and a large population of virus-affected people propel the Zika virus vaccines market growth. Various vaccines are being developed to protect against viruses, such as mRNA, DNA-based, genetically engineered and inactivated vaccines. With the rise in zika virus incidences, many pharmaceutical and biotechnology companies are investing in this market. In a very rare case, the zika virus is also transmitted through blood transfusion. In 2016, the World Health Organization (WHO) declared that the major causes of the zika virus were asymptomatic.

The growing number of collaborations and partnerships between governments, pharmaceutical companies, research institutions, and non-profit organizations to support the development and production of Zika virus vaccines, the rising trend of international travel and tourism and increasing awareness of the risks of Zika virus to pregnant women favor the market growth. The growing support from regulatory bodies such as implementing fast-track pathways, streamlined regulatory processes and expedited reviews, increasing number of awareness campaigns and initiatives by international organizations such as the World Health Organization (WHO) to combat the spread of Zika virus and the potential for future Zika virus outbreaks further boost the market’s growth rate.

MARKET RESTRAINTS:

The scientific and technical challenges associated with the development of safe and effective Zika virus vaccines majorly hamper the market growth. Stringent assessments of the safety, efficacy and quality of Zika virus vaccines by the regulatory bodies challenge the market growth. High costs associated with the development of Zika virus vaccines, vaccine hesitancy or reluctance among the public and the presence of other preventive measures such as vector control, public health education, and personal protection measures further impede the market growth.

Impact of COVID-19 on the global zika virus vaccines market:

COVID-19 was declared a global pandemic in 2020. In Asia, pregnant women were identified as vulnerable based on previous exposure to similar viral diseases like H1N1 influenza and severe acute respiratory syndrome (SARS). Both viruses are dangerous to pregnant women's health, and as recently emerging pathogens, they are plagued by diagnostic, prognostic and therapeutic ambiguity, posing challenges for physicians and patients. Another emerging viral concern, the Zika flavivirus, has been overshadowed by the unexpected and widespread outbreak of coronavirus (SARS-CoV-2). Regarding limited diagnostic capabilities, treatments, and prognostic uncertainty, ZIKA illness and COVID-19 are very similar. Both illnesses are linked to a considerable risk of negative consequences for the pregnant woman or the fetus. In vulnerable communities, existing social and economic inequalities exacerbate the risk of ZIKA illness and COVID-19. Even though each pathogen has its characteristics, there are underlying fundamental principles for recognizing, communicating, and mitigating infection risk. Both viruses are dangerous to pregnant women's health, and as newly emerging pathogens, they are plagued by diagnostic, prognostic and therapeutic uncertainty, posing difficulties for physicians and patients alike. Considering all these factors, the zika virus vaccine market has had favorable growth during the pandemic.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2022 to 2028

Base Year

2022

Forecast Period

2023 to 2028

Segments Covered

By Type, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

 

This research report on the global zika virus vaccines market has been segmented and sub-segmented based on type, end-user, and region.

Zika Virus Vaccines Market - By Type:

  • Therapeutic Vaccines
  • Preventive Vaccines

Based on type, the therapeutic vaccines segment is anticipated to grow with the fastest CAGR in the global market for zika virus vaccines during the forecast period. The growing number of Zika virus infections worldwide creates a strong demand for therapeutic vaccines and is driving the growth of therapeutic vaccines. The potential of therapeutic vaccines in reducing the severity of symptoms and complications associated with Zika virus infection and the growing need to address the current lack of specific antiviral treatments for Zika virus infection further boost the segment’s growth rate.

The preventive vaccines segment is anticipated to account for a promising share of the global market during the forecast period. The efforts from governments and public health organizations worldwide to promote vaccination as a preventive measure against Zika virus infection are one of the key factors propelling the segmental growth. The growing need for preventive vaccines to protect pregnant women and their unborn children from Zika virus infection and the rising demand for preventive vaccines among travelers and individuals residing in or traveling to Zika-affected areas further boost the growth rate of the segment.

Zika Virus Vaccines Market - By End-User:

  • Hospitals
  • Clinics
  • Research Institutes
  • Others

Based on end-user, the hospital segment held the largest share of the global market in 2022 and this trend is projected to continue throughout the forecast period. The growing healthcare infrastructure especially in developing regions supporting the administration and distribution of Zika virus vaccines in hospitals, the availability of vaccines in hospitals and collaborations of hospitals with pharmaceutical companies and research institutions to conduct clinical trials and vaccine distribution programs drive the growth of the hospital segment.

The clinic segment had the second-largest share of the global market in 2022 and is predicted to grow at a steady CAGR during the forecast period. The convenience and proximity of clinics, the emphasis of clinics on preventive care and vaccination programs and targeted outreach programs, such as community health campaigns and educational initiatives by clinics contribute to the growth of the clinics segment.

Zika Virus Vaccines Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, Latin America dominated the worldwide Zika virus vaccine market in 2022, and this trend is projected to continue over the forecast period. The region's supremacy can be ascribed to the rising number of persons infected with the Zika virus in countries like Brazil, Bolivia, and Peru and the presence of key players. The rise in Zika-infected people is expected to spur effective vaccinations to reduce infection rates. This increases the level of preparedness in the event of future Zika outbreaks. As a result, it can boost Zika vaccine demand and provide opportunities for critical companies over the forecast period. Zika fever has infected the populations of 69 countries, causing mild disease, and has spread over Central and South America.

The Asia Pacific regional market is predicted to grow rapidly during the forecast period. The high population density and favorable mosquito vectors in the Asia-Pacific region majorly drive the growth of the APAC market. Rising healthcare expenditure in countries across the Asia-Pacific region, growing focus on public health initiatives and immunization programs and the implementation of proactive measures to combat Zika virus transmission by the governments of APAC countries further drive the APAC market growth.

The MEA market is anticipated to hold a considerable share of the global market during the forecast period owing to the growing investments in healthcare infrastructure, improving access to immunization programs, emerging outbreaks and international collaborations with research organizations and pharmaceutical companies to address public health challenges to promote the MEA market growth.

KEY MARKET PLAYERS:

Some of the most prominent companies leading the global zika virus vaccines market profiled in this report are Takeda Pharmaceutical Co. Ltd., NewLink Genetics Co., Immunovaccine Inc., GeneOne Life Science Inc., GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., Bharat Biotech International Ltd., Hawaii Biotech Inc., and Sanofi S.A.

RECENT MARKET HAPPENINGS:

  • In June 2016, the FDA approved the first human clinical trial for GLS–5700, an Inovio Pharmaceuticals zika vaccine being produced. The distribution of phase I-IV clinical trials suggests that most Zika virus trials were in phase I. In 2017, the NIAID Vaccine Research Center (VRC) accepted a phase 2 clinical studies grant for a DNA vaccine.
  • Sanofi S.A initiated a vaccine research and development initiative in early 2016 with the release of Dengvaxia (Dengue vaccine) to help the company identify and develop an effective vaccine against the Zika virus.
  • In early 2016, the WHO introduced a global public awareness program through its Strategic Response Program and Joint Strategy for Zika. This strategy outlines all the issues at the time of infections to be taken care of. Further, in mid-2016, by publishing Zika Risk Assessment for the European Region, the WHO Regional Office for Europe established a learning program to raise awareness.

Please wait. . . . Your request is being processed

FAQ's

How big is the global zika virus vaccines market?

The global zika virus vaccine market size was valued at USD 16.11 billion in 2021.

What is the growth rate of the global global zika virus vaccines market?

Between 2022 to 2027, the global zika virus vaccines market is estimated to grow at a CAGR of 5.4%.

Which region is growing the fastest in the global zika virus vaccines market?

During the forecast period, the Asia-Pacific is anticipated to be growing the fastest in the global market.

What are the companies playing a leading role in the zika virus vaccine market?

Takeda Pharmaceutical Co. Ltd., NewLink Genetics Co., Immunovaccine Inc., GeneOne Life Science Inc., GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., Bharat Biotech International Ltd., Hawaii Biotech Inc., and Sanofi S.A. are a few of the notable companies in the global market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample